サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790211

米国の低分子創薬アウトソーシング市場規模、シェア、動向分析レポート：ワークフロー別、サービス別、治療領域別、最終用途別、セグメント予測、2025年～2033年

U.S. Small Molecule Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow, By Service, By Therapeutics Area, By End Use, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
米国の低分子創薬アウトソーシング市場規模、シェア、動向分析レポート：ワークフロー別、サービス別、治療領域別、最終用途別、セグメント予測、2025年～2033年
出版日: 2025年07月24日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の低分子創薬アウトソーシング市場概要

米国の低分子創薬アウトソーシング市場規模は2024年に15億2,000万米ドルと推定され、2033年には34億7,000万米ドルに達すると予測され、2025～2033年のCAGRは9.7%で成長します。研究開発費の増加、初期段階の研究活動への注目の高まり、社内リソースが限られているバイオテクノロジー企業の成長が市場を牽引しています。

また、アウトソーシングは、製薬企業やバイオテクノロジー企業にとって、タイムラインの迅速化、固定間接費の削減、医薬品化学、ヒット・ツー・リード最適化、ADME/PK検査、IND取得活動などのセグメントにおける専門知識の獲得を目指す戦略的選択肢として浮上しています。

AIを活用した化合物設計、CRISPRを活用した対象バリデーション、高性能スクリーニング、3D細胞モデルなどの革新的な技術により、創薬プロセスが変革され、医薬品開発業務受託機関（CRO）はより効率的で予測可能な結果を提供できるようになります。さらに、研究開発コストの上昇、医薬品開発需要の増加、バーチャル医薬品モデルへのシフトが市場を支えています。さらに、登録臨床検査の増加、低分子医薬品の承認率の向上、医療技術の進歩、研究対象疾患の増加、新たな治療に対する緊急のニーズが市場を牽引すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の低分子創薬アウトソーシング市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 臨床検査件数分析（2024年）
    • 国別臨床検査総数
    • 相別臨床検査総数
    • 研究デザイン別臨床検査総数
    • 主要治療領域別臨床検査総数
  • 価格モデル分析
  • 技術
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • SWOT分析によるPESTEL

第4章 米国の低分子創薬アウトソーシング市場：ワークフロー別、推定・動向分析

  • 米国の低分子創薬アウトソーシング市場（ワークフロー別）：セグメントダッシュボード
  • 米国の低分子創薬アウトソーシング市場（ワークフロー別）：変動分析
  • ワークフロー別、2021～2033年
  • 対象の特定とスクリーニング
  • 対象検証と機能情報科学
  • リード特定と候補者最適化
  • 前臨床開発
  • その他

第5章 米国の低分子創薬アウトソーシング市場：サービス別、推定・動向分析

  • 米国の低分子創薬アウトソーシング市場（サービス別）：セグメントダッシュボード
  • 米国の低分子創薬アウトソーシング市場（サービス別）：変動分析
  • サービス別、2021～2033年
  • 化学サービス
  • 生物学サービス

第6章 米国の低分子創薬アウトソーシング市場：治療領域別、推定・動向分析

  • 米国の低分子創薬アウトソーシング市場（治療領域別）：セグメントダッシュボード
  • 米国の低分子創薬アウトソーシング市場（治療領域別）：変動分析
  • 治療領域別、2021～2033年
  • 呼吸器系
  • 痛みと麻酔
  • 腫瘍学
  • 眼科
  • 血液学
  • 心血管系
  • 内分泌
  • 胃腸
  • 免疫調節
  • 抗感染性
  • 中枢神経系
  • 皮膚科
  • 泌尿生殖器系

第7章 米国の低分子創薬アウトソーシング市場：最終用途別、推定・動向分析

  • 米国の低分子創薬アウトソーシング市場（最終用途別）：セグメントダッシュボード
  • 米国の低分子創薬アウトソーシング市場（最終用途別）：変動分析
  • 用途別、2021～2033年
  • 製薬バイオテクノロジー企業
  • 学術機関

第8章 競合情勢

  • 市場参入企業の分類
    • マーケットリーダー
    • 新興参入企業
  • 企業市場シェア/評価分析、2024年
  • 企業プロファイル
    • Charles River Laboratories
    • Laboratory Corporation of America Holdings（Covance）
    • Albany Molecular Research（Curia）
    • Merck & Co., Inc.
    • QIAGEN
    • Eurofins
    • Evotec
    • GenScript BIoTech
    • Pharmaron
    • Syngene International
    • Dalton Pharma Services
    • Oncodesign
    • Jubilant Biosys
    • Domainex
    • Dr. Reddy Laboratories Ltd.
    • Pharmaron Beijing Co., Ltd.
    • TCG Lifesciences Pvt Ltd.

第9章 主要推奨事項

図表

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 U.S. Small Molecule Drug Discovery Outsourcing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 5 U.S. Small Molecule Drug Discovery Outsourcing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6 U.S. Small Molecule Drug Discovery Outsourcing Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 7 U.S. Small Molecule Drug Discovery Outsourcing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. small molecule drug discovery outsourcing market dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Small molecule drug discovery outsourcing market: workflow outlook and key takeaways
  • Fig. 20 U.S. small molecule drug discovery outsourcing market: workflow movement analysis
  • Fig. 21 Target identification & screening market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Target validation & functional informatics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Lead identification & candidate optimization market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Preclinical development market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Other market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. small molecule drug discovery outsourcing market: Service outlook and key takeaways
  • Fig. 27 U.S. small molecule drug discovery outsourcing market: Service movement analysis
  • Fig. 28 Chemistry services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Biology services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. small molecule drug discovery outsourcing market: therapeutics area outlook and key takeaways
  • Fig. 31 U.S. small molecule drug discovery outsourcing market: therapeutics area movement analysis
  • Fig. 32 Respiratory system market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Pain and anesthesia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Ophthalmology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Hematology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Cardiovascular market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Endocrine market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Gastrointestinal market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Immunomodulation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Anti-infective market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Central nervous system market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Dermatology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Genitourinary system market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. small molecule drug discovery outsourcing market: End use outlook and key takeaways
  • Fig. 46 U.S. small molecule drug discovery outsourcing market: End use movement analysis
  • Fig. 47 Pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Academic institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key company categorization
  • Fig. 50 Service heat map analysis
  • Fig. 51 Strategic framework
目次
Product Code: GVR-4-68040-687-1

U.S. Small Molecule Drug Discovery Outsourcing Market Summary

The U.S. small molecule drug discovery outsourcing market size was estimated at USD 1.52 billion in 2024 and is projected to reach USD 3.47 billion by 2033, growing at a CAGR of 9.7% from 2025 to 2033. Increasing R&D expenses, rising focus on early-stage research activities, and growing biotech companies with limited in-house resources drive the market.

Besides, outsourcing has emerged as a strategic option for pharmaceutical and biotech companies aiming to accelerate the timelines, lower fixed overhead costs, and gain access to specialized expertise in areas such as medicinal chemistry, hit-to-lead optimization, ADME/PK studies, and IND-enabling activities.

Innovations like AI-driven compound design, CRISPR-based target validation, high-throughput screening, and 3D cell models transform discovery processes, enabling contract research organizations (CROs) to provide more efficient and predictive results. Furthermore, rising R&D costs, increased demand for drug development, and a shift towards virtual pharmaceutical models support the market. In addition, an increase in registered clinical studies, a higher approval rate for small molecule drugs, advancements in medical technology, a rise in diseases being studied, and the urgent need for new treatments are anticipated to drive the market.

U.S. Small Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. small molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, and end use:

  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Target Identification & Screening
  • Target Validation & Functional Informatics
  • Lead Identification & Candidate Optimization
  • Preclinical Development
  • Others
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemistry Services
  • Biology Services
  • Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Respiratory system
  • Pain and Anesthesia
  • Oncology
  • Ophthalmology
  • Hematology
  • Cardiovascular
  • Endocrine
  • Gastrointestinal
  • Immunomodulation
  • Anti-infective
  • Central Nervous System
  • Dermatology
  • Genitourinary System
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology companies
  • Academic Institutes

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Workflow
    • 1.2.2. Service
    • 1.2.3. Therapeutics Area
    • 1.2.4. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain-based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Small Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing demand for outsourcing services in drug development
      • 3.2.1.2. Technological advancements in drug discovery
      • 3.2.1.3. Rising shortening time-to-market pressures
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Intellectual property (IP) and data security concerns
      • 3.2.2.2. Limited standardization and reproducibility
  • 3.3. Clinical Trials Volume Analysis, (2024)
    • 3.3.1. Total Number Of Clinical Trials By Country
    • 3.3.2. Total Number Of Clinical Trials, By Phase
    • 3.3.3. Total Number Of Clinical Trials, By Study Design
    • 3.3.4. Total Number Of Clinical Trials, By Key Therapeutic Area
  • 3.4. Pricing Model Analysis
  • 3.5. Technology Landscape
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Small Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

  • 4.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
  • 4.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
  • 4.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
  • 4.4. Target Identification & Screening
    • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Target Validation & Functional Informatics
    • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Lead Identification & Candidate Optimization
    • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Preclinical Development
    • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Small Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

  • 5.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By Service: Segment Dashboard
  • 5.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By Service: Movement Analysis
  • 5.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 5.4. Chemistry Services
    • 5.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Biology Services
    • 5.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Small Molecule Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

  • 6.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
  • 6.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
  • 6.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
  • 6.4. Respiratory system
    • 6.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pain and Anesthesia
    • 6.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Ophthalmology
    • 6.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Hematology
    • 6.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Cardiovascular
    • 6.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Endocrine
    • 6.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Gastrointestinal
    • 6.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12. Immunomodulation
    • 6.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.13. Anti-infective
    • 6.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.14. Central Nervous System
    • 6.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.15. Dermatology
    • 6.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.16. Genitourinary System
    • 6.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Small Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

  • 7.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
  • 7.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By End Use: Movement Analysis
  • 7.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology companies
    • 7.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Academic Institutes
    • 7.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Share/Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Charles River Laboratories
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Laboratory Corporation of America Holdings (Covance)
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Albany Molecular Research (Curia)
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Merck & Co., Inc.
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. QIAGEN
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Eurofins
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Evotec
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. GenScript Biotech
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Pharmaron
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Syngene International
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Dalton Pharma Services
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Oncodesign
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Jubilant Biosys
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives
    • 8.3.14. Domainex
      • 8.3.14.1. Company Overview
      • 8.3.14.2. Financial Performance
      • 8.3.14.3. Service Benchmarking
      • 8.3.14.4. Strategic Initiatives
    • 8.3.15. Dr. Reddy Laboratories Ltd.
      • 8.3.15.1. Company Overview
      • 8.3.15.2. Financial Performance
      • 8.3.15.3. Service Benchmarking
      • 8.3.15.4. Strategic Initiatives
    • 8.3.16. Pharmaron Beijing Co., Ltd.
      • 8.3.16.1. Company Overview
      • 8.3.16.2. Financial Performance
      • 8.3.16.3. Service Benchmarking
      • 8.3.16.4. Strategic Initiatives
    • 8.3.17. TCG Lifesciences Pvt Ltd.
      • 8.3.17.1. Company Overview
      • 8.3.17.2. Financial Performance
      • 8.3.17.3. Service Benchmarking
      • 8.3.17.4. Strategic Initiatives

Chapter 9. Key Recommendations